REG - T.Rowe Price Assoc - Form 8.3 - [AbbVie Inc]

T Rowe PriceAnnouncement

26/02/2020 15:15

RNS Number : 2361E
  
T.Rowe Price Associates
  
26 February 2020
  
 

Ap19
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


 T. ROWE PRICE ASSOCIATES, INC.




Company dealt in


 ABBVIE INC




Class of relevant security to which the dealings being disclosed relate (Note 2)


 ISIN: US00287Y1091 




Date of dealing


 25 February 2020




2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 44,397,295                3.00%


 




(2) Derivatives (other than options)


 


 




(3) Options and agreements to purchase/sell


  


 




Total


 44,397,295                3.00%


 



 
 
 
 
 
 
 



 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)




Class of relevant security:


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 


 




 
(2) Derivatives (other than options)


 


 




 
(3) Options and agreements to purchase/sell


 


 




Total


 


 



 
 
 
 
 
 
 




 

Ap20
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




 
Purchase/sale


 
Number of relevant securities


 
Price per unit (Note 5)




Purchases
 
 
 
 
 
 
 
 
 
Sales
 
 
 
 


24,100
26,351
114,203
1,490
39,141
3,440
900
100
154,440
100
60,500
77
504


89.193 USD
89.286 USD
89.326 USD
89.631 USD
89.744 USD
90.860 USD
92.582 USD
92.650 USD
92.749 USD
92.844 USD
88.547 USD
89.330 USD
90.794 USD
 
 




 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)




 


 


 


 




 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 





 

Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


 26 February 2020




Contact name


 Gary Greb




Telephone number


 001 410 345 2527




If a connected EFM, name of offeree/offeror with which connected


 




If a connected EFM, state nature of connection (Note 10)


 




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEKKABKQBKDFBB